Dynavax Technologies Corporation develops and sells vaccines, primarily in the US. The company's primary vaccine, HEPLISAV-B, prevents hepatitis B infections caused by all known subtypes of hepatitis B virus. It also collaborates with other companies in the biopharmaceutical industry.